Summary
Merck (NYSE: MRK) has announced positive findings from the Phase 3 KEYNOTE-689 trial, which evaluated the use of KEYTRUDA® (pembrolizumab) as a perioperative treatment for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The interim analysis revealed that the addition of KEYTRUDA significantly improved event-free survival (EFS) compared to conventional treatment alone.
Over a median follow-up of 38.3 months, the findings indicated a reduction in EFS events among those receiving KEYTRUDA in conjunction with standard of care radiotherapy. Specifically, there was a 34% reduction in the risk of EFS events for patients with a combined positive score (CPS) ≥10.
This study marks a significant milestone as the first positive trial for this patient group in over twenty years and highlights the potential for KEYTRUDA to transform treatment options for LA-HNSCC patients.
Key Points
- KEYTRUDA significantly improves event-free survival compared to standard care in LA-HNSCC patients.
- 34% reduction in EFS events noted in patients with CPS ≥10 receiving KEYTRUDA treatment.
- This study represents the first positive trial in two decades for this patient group.
- KEYTRUDA therapy demonstrated a consistent safety profile without new safety signals.
- Merck is working with the FDA for expedited review of the treatment based on these findings.
Why should I read this?
If you’re interested in cancer research or treatment advancements, this article is a must-read! The breakthrough findings from the KEYNOTE-689 trial could revolutionise the way we approach treatment for locally advanced head and neck cancer, offering hope and new options for patients and healthcare providers alike. Don’t miss out on understanding how therapies like KEYTRUDA are paving the way for better cancer care!